Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia in Remission: early-phase trial registry
5 of 12 indexed Acute Myeloid Leukemia in Remission trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 5 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Acute Myeloid Leukemia in Remission: 12 US clinical trials tracked, 5 recruiting.
Acute Myeloid Leukemia in Remission is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.
Enrollment posture brief
Registry condition acute-myeloid-leukemia-in-remission
OPEN 5 | RECR 42% | LATE 0 | EARLY 9 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Alzheimer Disease, Early Onset (42% recruiting · 12 trials)
Acute Myeloid Leukemia in Remission lists 5 open slots (42% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myeloid Leukemia in Remission on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myeloid Leukemia in Remission is recruiting below its size-band peers.
5 of 12 indexed trials (41.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Acute Myeloid Leukemia in Remission research.
City of Hope Medical Center accounts for 2 of 12 trials (16.7%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Myeloid Leukemia in Remission trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 12 trials that report a genuine target (sentinel values excluded). 10 of those (83.3%) plan for fewer than 100 participants.
-
Acute Myeloid Leukemia in Remission research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Pilot Study of Reduced Venetoclax Exposure
Northwell Health
NCT07163793
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Medical College of Wisconsin
NCT05794880
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X
NCT06462365
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT03670966
Ziftomenib Maintenance Post Allo-HCT
Massachusetts General Hospital
NCT06440135
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Center for International Blood and Marrow Transplant Research
NCT05224661
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT02506933
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Massachusetts General Hospital
NCT03286530
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
M.D. Anderson Cancer Center
NCT04062266
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03192397
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT03560752
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Baylor College of Medicine
NCT05236764
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myeloid Leukemia in Remission records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myeloid Leukemia in Remission trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myeloid Leukemia in Remission page
12 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Acute Myeloid Leukemia in Remission trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Acute Myeloid Leukemia in Remission trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myeloid Leukemia in Remission condition card totals 12 registered trials; most-linked intervention Multi-peptide CMV-Modified Vaccinia Ankara Vaccine; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.